L
The announcement is from those who make workers happy, first of all. Gsk, the multinational that bought Novartis, has said it is keeping the Siena research and development department alive.
Positive change of course for the pharmaceutical company which after doing the math has modified the initial project which envisaged the sale of this branch of the company because it is a duplicate of what it already has in Belgium. GSK understood the importance of Sienese research and development workers and decided to keep them working.
“We are satisfied with the decision taken by the company – he told Antenna Radio Esse Marco Goracci, Filctem CGIL secretary – after 23 months of close confrontation which began when the company, announcing the reorganisation, said it already had a research center and Siena would have had to do without this department.
We have expressed our opposition, we have tried to make it clear that without the development center the company would have been weaker and we have been convincing. Gsk has not only decided to keep the development department but also to enhance it with other projects. Now we expect him not only to focus on meningitis vaccines but also to transfer other types of products to Siena. It would be the best guarantee to keep the Sienese site among the most important in the world”.
Mar 17, 2016 – antennaradioesse
_______________________________________
GSK communication
Update on the GSK Vaccines integration process
-
GSK Vaccines will maintain the Technical Research & Development activities at the Siena site in support of its Research and Development Center
-
TRD activities will continue in line with the new global R&D organization of the Vaccines division with a long-term vision
-
The capital of skills and professionalism was maintained in the area with the reconfirmation of Siena and Rosia as a strategic hub in the GSK Vaccines network
-
The new global structure of the Finance function was also presented
GSK Vaccines announced today that it will maintain the Technical Research & Development (TRD) activities within its Tuscan hub to support the Research and Development Center of Siena. This is an important confirmation for the Siena and Rosia site, further reinforcing its long-term strategic relevance within GSK's global network.
After an initial analysis, which assumed the consolidation of most of the TRD activities in Belgium and the consequent evaluation of negotiations with potential third parties, a further analysis was conducted and it was established that the value of the TRD justifies keeping it within of the Siena site. This is due to the key role played by the TRD in supporting the meningitis projects, which will be decisive for the future of the company around the world and, simultaneously, to the benefit of a broader Vaccines portfolio.
The TRD department of Siena is now confirmed within the GSK Vaccines Research & Development network, maintaining an organization in Italy that will include 150 collaborators, including TRD support activities. The structure of this organization will be defined over the next few months. Furthermore, in line with the integration process announced on 2 December, GSK Vaccines presented the new global organization of the Finance function.
In the new organisation, this function will be integrated within GSK's centralized operating model, guaranteeing a sustainable, efficient and competitive business. There are 18 unconfirmed positions in the new organization of the Finance function of Siena and Rosia, while those of the TRD are 25.
GSK Vaccines is now committed to launching a consultation process, which it will conduct in a transparent manner in compliance with the values of integrity and people, to minimize the impact and find constructive solutions for the benefit of individuals, the Siena site and Rosia and the reference area.
GlaxoSmithKline is a research-based pharmaceutical company, a world leader in ethical medicines, vaccines and consumer health products, committed to improving the quality of human life, to enable people to be more active, to feel better, to live longer .
